This is a multicenter expanded access protocol to provide human leukocyte antigen (HLA) partially-matched third-party allogeneic EBV-CTLs for the treatment of EBV-associated viremia and disease for which there is no comparable or satisfactory alternative therapy to treat the patient's disease or condition. Patients must not be eligible to enroll in clinical trials designed to support the development and marketing approval of Atara EBV-CTLs. Allogeneic third-party EBV-CTL will be selected for the patient from the bank of available EBV-CTL cell product lots based on having a partial HLA match and having an appropriate HLA restriction shared between the EBV-CTL donor and the patient's EBV associated viremia/disease or the patient, as appropriate for the disease setting. EBV-CTLs will be administered in cycles lasting 5 weeks (35 days). During each cycle, patients will receive intravenous (IV) EBV-CTLs on Days 1, 8, and 15, followed by an observation period to complete a 35-day cycle.